Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a vector set includes a first vector and a second vector. The first vector includes a transposase target sequence, a first promoter sequence ligated to downstream of the transposase target sequence, and a first reporter gene ligated to downstream of the first promoter sequence. The second vector includes a 5?-side transposase recognition sequence, a 3?-side transposase recognition sequence, and a first enhancer sequence arranged therebetween.

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a modified piggyBac transposase polypeptide includes a piggyBac transposase amino acid sequence and a nuclear localization signal amino acid sequence.

Abstract: According to one embodiment, a composition is for delivering an objective substance to the T-cell malignant tumor cell. The composition contains a substance delivery carrier. The substance delivery carrier has a lipid particle, and the objective substance encapsulated in the lipid particle. The lipid particle contains, as constituents thereof, at least a first lipid represented by formula (I) and a second lipid represented by formula (II).

Abstract: According to one embodiment, there is provided a method of producing a gene modification T cell (CAR-T cells) which expresses a chimeric antigen receptor (CAR). This method includes stimulating a cell population containing a T cell with an antibody which activates the T cell, bringing the cell population into contact with a nucleic acid-introducing carrier, wherein the nucleic acid-introducing carrier containing a lipid particle, a first nucleic acid and containing a CAR gene, and a second nucleic acid containing a transposase gene encapsulated in the lipid particle, and culturing the cell population after the contacting.

Abstract: According to one embodiment, a nucleic acid delivery carrier is used to integrate a first sequence into a genome of cells. The nucleic acid delivery carrier includes a donor DNA containing the first sequence, an RNA agent containing at least an RNA encoding a protein involving integration of the first sequence into the genome, and a lipid particle encapsulating the donor DNA and the RNA agent.

Abstract: According to one embodiment, an examination device includes a reagent, a sheet and a detection unit. The reagent reacts with a measurement target and thereby causes light emission. The sheet is capable of adsorbing the reagent and gradually releasing the adsorbed reagent. The detection unit detects optical characteristics of the light emission caused by the reaction between the measurement target and the reagent.

Abstract: [Problem] To provide a biodegradable compound having a structure decomposed in a cell, lipid particles containing the compound, and a pharmaceutical composition comprising the lipid particles. [Solution] The compound of the embodiment is represented by the formula (1): P—[X—R—Y—R?-Q]2 (1). In the formula, P is an alkyleneoxy having an ether bond, X is a divalent linking group having a tertiary amine structure, R is a divalent linking group, R? is a single bond or a C1 to C6 alkylene, and Q is a liposoluble vitamin residue, a sterol residue, or a C12 to C22 aliphatic hydrocarbon group. The structure of the compound contains at least one biodegradable group. From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a nucleic acid condensing peptide includes one terminal having a first sequence RRRRRR and another terminal having a second sequence RQRQR. Between the first sequence and the second sequence, none or one or more intermediate sequences each consisting of RRRRRR or RQRQR are included. Further, of the first sequence, the second sequence and the intermediate sequences, two or more neutral amino acids are included between any two sequences adjacent to each other.

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: The compound according to the present embodiment is represented by the following formula (1): Q-L-CHR2??(1) (wherein, Q is a non-cationic aliphatic group that does not contain nitrogen but contains oxy; L is a single bond or an aliphatic group containing no nitrogen; Rs are C12-C24 aliphatic group, the same or different; and at least one R contains, in the main chain or side chain thereof, a linking group LR selected from the group consisting of —C(?O)—O—, —O—C(?O)—, —O—C(?O)—O—, —S—C(?O)—, —C(?O)—S—, —C(?O)—NH—, and —NH—C(?O)—).

Abstract: [Problem] To provide a biodegradable compound having a structure decomposed in a cell, lipid particles containing the compound, and a pharmaceutical composition comprising the lipid particles. [Solution] The compound of the embodiment is represented by the formula (1): P—[X—R—Y—R?-Q]2 (1). In the formula, P is an alkyleneoxy having an ether bond, X is a divalent linking group having a tertiary amine structure, R is a divalent linking group, R? is a single bond or a C1 to C6 alkylene, and Q is a liposoluble vitamin residue, a sterol residue, or a C12 to C22 aliphatic hydrocarbon group. The structure of the compound contains at least one biodegradable group. From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a nucleic acid condensing peptide includes one terminal having a first sequence RRRRRR and another terminal having a second sequence RQRQR. Between the first sequence and the second sequence, none or one or more intermediate sequences each consisting of RRRRRR or RQRQR are included. Further, of the first sequence, the second sequence and the intermediate sequences, two or more neutral amino acids are included between any two sequences adjacent to each other.

Abstract: The compound according to the present embodiment is represented by the following formula (1): Q-L—CHR2 ??(1) (wherein, Q is a non-cationic aliphatic group that does not contain nitrogen but contains oxy; L is a single bond or an aliphatic group containing no nitrogen; Rs are C12-C24 aliphatic group, the same or different; and at least one R contains, in the main chain or side chain thereof, a linking group LR selected from the group consisting of —C(?O)—O—, —O—C(?O)—, —O—C(?O)—O—, —S—C(?O)—, —C(?O)—S—, —C(?O)—NH—, and —NH—C(?O)—).

Abstract: According to one embodiment, a first gene encodes a reporter protein. The first gene is disposed at the downstream of the gene promoter. A second gene is disposed at the downstream of the gene promoter and encodes a replication origin-binding protein. An internal ribosome entry site is disposed between the first gene and the second gene. The transcription termination signal sequence encodes a signal for terminating the transcription of the first gene and the second gene. A replication origin sequence is recognized by the replication origin-binding protein.

Abstract: According to one embodiment, a reporter vector includes a first and a second reporter gene expression unit and a replication initiation sequence. The first reporter gene expression unit includes a promoter sequence of a cell characteristics marker, a first reporter gene, and a first transcription termination sequence. The second reporter gene expression unit includes a promoter sequence exhibiting constitutive activity, a second reporter gene, a bicistronic expression sequence, a replication initiation protein gene, and a second transcription termination sequence. The replication initiation sequence binds to a replication initiation protein, thereby initiating replication of the reporter vector.

Abstract: According to one embodiment, a reporter vector presenting an extracellular binding capacity to metallic compounds contains a nucleotide sequence exhibiting a promoter activity depending on a specific condition, a nucleotide sequence encoding a metallic compound-binding peptide presented extracellularly, and a nucleotide sequence encoding transcription termination signals.

Abstract: According to one embodiment, a method of obtaining epigenetic information of a subject cell containing a specific genome sequence is provided. The method includes, introducing a reporter nucleic acid construct into the cell, culturing the cell to promote the construct to self-replicate, detecting a signal produced, and obtaining the information. The construct contains a target sequence containing a base with a substitutable group, and having homology with the specific genome sequence. The construct transcribes a state of modification of the specific genome sequence onto the target sequence during the self-replication, by a substitution of the group in the target sequence. The construct produces a signal depending on a states of the substitution of the group in the target sequence.